At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 134 enrolled
Drug / intervention
Convalescent plasmabiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma
Hospital de Infecciosas Francisco Javier Muniz·interventional·Posted Jul 13, 2020·Updated Aug 25, 2021
In Brief
A Phase 2 clinical trial evaluating Convalescent plasma for SARS-Associated Coronavirus and 2 related conditions. Completed, enrolled 134 participants across 1 site.
Detailed Summary
This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-Associated Coronavirus, Covid19, SARS-CoV Infection
CountriesArgentina
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartJun 2020
First PostedJul 2020
Primary CompletionJan 2021
Study CompletionJun 2021
TodayJul 2026
First PostedJul 13, 2020
Enrollment StartJun 25, 2020
Primary CompletionJan 19, 2021
Study CompletionJun 19, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.0 years ago
Interventions
Convalescent plasmabiological
Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies